{"id":"NCT01370616","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)","officialTitle":"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-02","primaryCompletion":"2013-12-08","completion":"2013-12-18","firstPosted":"2011-06-10","resultsPosted":"2014-12-02","lastUpdate":"2018-08-27"},"enrollment":565,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Infection; Diabetic Foot"],"interventions":[{"type":"DRUG","name":"Ertapenem sodium","otherNames":["MK-0826, INVANZ™"]},{"type":"DRUG","name":"Piperacillin/tazobactam sodium","otherNames":["Tazocin™"]},{"type":"DRUG","name":"Piperacillin/tazobactam-matching placebo","otherNames":[]},{"type":"DRUG","name":"Amoxicillin/clavulunate potassium","otherNames":[]}],"arms":[{"label":"Ertapenem sodium","type":"EXPERIMENTAL"},{"label":"Piperacillin/tazobactam sodium","type":"ACTIVE_COMPARATOR"}],"summary":"This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections. The primary hypothesis was that treatment with ertapenem sodium is non-inferior to treatment with piperacillin/tazobactam sodium, in achieving clinical improvement or cure.","primaryOutcome":{"measure":"Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV)","timeFrame":"Day 5 up to Day 28","effectByArm":[{"arm":"Ertapenem Sodium","deltaMin":93.6,"sd":null},{"arm":"Piperacillin/Tazobactam Sodium","deltaMin":97.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26888908"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":275},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Pyrexia","Hypoglycaemia","Constipation"]}}